Salzmann Peter
Known title: Chief Executive OfficerCIK: 0001796309
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Transaction History
| IMVT | ▼ Sell | Open Market | 8,321 | $124K | 4/16/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 28,094 | $365K | 4/9/2025 | View on chart |
| IMVT | ▲ Buy | Grant | 265,820 | $0 | 4/1/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 15,439 | $322K | 2/19/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 8,352 | $199K | 1/15/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 415 | $10K | 1/15/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 5,105 | $123K | 1/8/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 16,692 | $425K | 11/20/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 9,095 | $262K | 10/16/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 4,460 | $132K | 10/9/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 14,470 | $461K | 8/21/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 598 | $19K | 8/21/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 510 | $16K | 7/17/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 8,175 | $242K | 7/17/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 4,619 | $130K | 7/9/2024 | View on chart |
| CRBP | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 16,163 | $479K | 5/22/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 26,365 | $759K | 4/17/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 7,714 | $231K | 4/17/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 4,807 | $150K | 4/9/2024 | View on chart |
| IMVT | ▲ Buy | Grant | 160,534 | $0 | 4/2/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 13,454 | $486K | 2/22/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 3,824 | $148K | 1/5/2024 | View on chart |
| IMVT | ▼ Sell | Open Market | 15,601 | $511K | 11/22/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 616 | $21K | 11/22/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 894 | $32K | 10/5/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 4,345 | $158K | 10/5/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 50,866 | $1.1M | 8/30/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 5,908 | $133K | 8/30/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 91,744 | $2.0M | 8/14/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 11,314 | $249K | 8/14/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 101,339 | $2.2M | 8/7/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 3,233 | $64K | 7/12/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 3,395 | $52K | 4/18/2023 | View on chart |
| IMVT | ▲ Buy | Grant | 243,832 | $0 | 4/12/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 4,021 | $68K | 1/11/2023 | View on chart |
| IMVT | ▼ Sell | Open Market | 2,793 | $26K | 10/13/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 1,605 | $7K | 9/28/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 1,644 | $10K | 8/30/2022 | View on chart |
| IMVT | ▲ Buy | Grant | 451,264 | $0 | 8/17/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 1,528 | $7K | 7/27/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 1,376 | $6K | 6/29/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 1,471 | $6K | 5/24/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 1,622 | $8K | 4/27/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 19,227 | $113K | 3/24/2022 | View on chart |
| IMVT | ▼ Sell | Open Market | 125,158 | $907K | 1/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Immunovant (IMVT) releases Q1 2027 earnings call transcript
Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.
Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.